Report Overview

Canadian Human Papillomavirus Vaccine Market size stood at USD XX Billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period 2019-2028.

In Canada, immunization against HPV types 16 and 18 contained in HPV2, HPV4, and HPV9 vaccine can prevent approximately 70% of cervical cancers and 60% of high-risk precancerous cervical lesions. Immunization against HPV types 31, 33, 45, 52, and 58 contained in the HPV9 vaccine could further prevent up to 17% of cervical cancers and 30% of high-risk precancerous cervical lesions. Immunization with either HPV4 or HPV9 vaccine can prevent approximately 90% of genital warts. The HPV vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. The growing burden of human papillomavirus infections in emerging economies to boost the HPV market in Canada. This vaccine market includes many pipeline products, increasing research for the therapeutic vaccine, the governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.



Market Drivers

The increasing prevalence of cervical cancer among female, increasing need to reduce HPV infections, a large number of pipeline products, increasing research for the therapeutic vaccine, the governments initiatives in imposing stringent policies for supplying vaccines to eradicate the burden of this disease, growing investments in research and development for introduction of novel immunization remedies for this virus are likely to create lucrative growth opportunities for the market.